Latest Health News

Page 2 of 271
Revvity has set out a long-range growth strategy built around AI-enabled scientific discovery, recurring software revenue and specialised diagnostics. The plan includes double-digit adjusted EPS growth, margin expansion and about US$5 billion of capital capacity through 2031, but formal 2027 guidance is still pending.
Ada Torres
Ada Torres
14 Nov 2026
Mach7 Technologies has signed Temple Health to a five-year licence for its eUnity Viewer and Vendor Neutral Archive, with Year 1 annual recurring revenue expected to reach A$0.5 million. The revenue will depend on go-live and first productive use, forecast within six to 12 months.
Victor Sage
Victor Sage
13 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Artrya has signed its first inbound US customer outside its foundation and research relationships, securing a five-year HonorHealth agreement with a minimum value of US$0.5 million. The Salix platform will be deployed across the Arizona health system’s nine-hospital CCTA network.
Victor Sage
Victor Sage
13 Nov 2026
Ramsay Santé has secured approval for a foreign exempt listing on the ASX, clearing a key operational hurdle for Ramsay Health Care’s proposed demerger. The transaction remains conditional on shareholder, Court and other approvals, with CDI trading provisionally scheduled to begin from 1 December.
Ada Torres
Ada Torres
12 Nov 2026
Alcidion has entered FY27 with record contracted revenue, a debt-free balance sheet and reaffirmed guidance for revenue and underlying EBITDA to exceed FY26. Shareholders also approved a 10-for-1 share consolidation as the healthcare software company weighs buy-backs, acquisitions and further platform investment.
Victor Sage
Victor Sage
12 Nov 2026
Peak Processing has secured the maximum five-year renewal for its Oldcastle, Ontario processing and sensory licence, replacing a sequence of one-year approvals. The longer term gives the ASX-listed THC beverage manufacturer more certainty as it scales production and adds product formats.
Victor Sage
Victor Sage
11 Nov 2026
FDC Consolidated Holdings has lifted its FY27 revenue guidance to $2.00-$2.08 billion and normalised EBIT guidance to $105-$110 million. The upgrade follows project execution, unaudited earnings performance and new contract wins, while its order book has grown 14% since June.
Victor Sage
Victor Sage
11 Nov 2026
Radius Health lifted first-half net profit attributable to shareholders by 27% to NZ$8.0 million and raised its interim dividend by 10% as occupancy remained strong. The aged-care operator also increased its FY27 earnings target, although debt and cash flow provide a counterweight to the upbeat result.
Ada Torres
Ada Torres
11 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Memphasys has secured its first New Zealand commercial agreement for Felix, committing a government-operated Auckland IVF clinic to a minimum of 1,200 cartridges over two years. The deal expands the device’s installed-clinic footprint, although undisclosed pricing leaves its financial contribution unclear.
Ada Torres
Ada Torres
9 Nov 2026
Biome Australia has secured an exclusive mainland China cross-border e-commerce agreement with H&S Global, targeting A$2.0 million in Year 1 purchases from an early 2027 launch. The target is larger than Biome’s entire FY26 international sales, but the company will fund 25% of Year 1 invoiced value in marketing and operational support.
Ada Torres
Ada Torres
9 Nov 2026

Browse the archive

Full archive